A new study led by the University of Toronto (U of T) has discovered a possible biomarker linked to multiple sclerosis (MS) ...

Last month, the FDA declined to approve Sanofi’s tolebrutinib for a specific form of multiple sclerosis. In a recently ...

The FDA rejected Sanofi's MS drug tolebrutinib, citing liver injury risks, unclear benefits, and trial data that failed to ...

Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the ...

ABLE United, Florida's official ABLE program, celebrates the federal expansion of eligibility for ABLE accounts under the ...

NICE has recommended natalizumab for adults with highly active RRMS, citing pregnancy suitability, biosimilar value and NHS ...

The 4th Circuit ruled an ALJ wrongly discounted a claimant’s fibromyalgia testimony and ordered Social Security benefits ...

The Department for Work and Pensions (DWP) has responded in the wake of a new report looking at the financial implications of ...

The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...

The disability community is entering into a new era of inclusion and opportunity. For nearly 10 years, ABLE United has ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...